dc.contributor.author | Faustini, SE | |
dc.contributor.author | Hall, A | |
dc.contributor.author | Brown, S | |
dc.contributor.author | Roberts, S | |
dc.contributor.author | Hill, H | |
dc.contributor.author | Stamataki, Z | |
dc.contributor.author | (PITCH) consortium, | |
dc.contributor.author | Jenner, MW | |
dc.contributor.author | Owen, RG | |
dc.contributor.author | Pratt, G | |
dc.contributor.author | Cook, G | |
dc.contributor.author | Richter, A | |
dc.contributor.author | Drayson, MT | |
dc.contributor.author | Kaiser, MF | |
dc.contributor.author | Heaney, JLJ | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-06-02T10:28:00Z | |
dc.date.available | 2023-06-02T10:28:00Z | |
dc.date.issued | 2023-06-01 | |
dc.identifier.citation | British Journal of Haematology, 2023, 201 (5), pp. 845 - 850 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5824 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.doi | 10.1111/bjh.18714 | |
dc.description.abstract | Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM. | |
dc.format | Print-Electronic | |
dc.format.extent | 845 - 850 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | British Journal of Haematology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | anti-CD38 | |
dc.subject | antibodies | |
dc.subject | high-dose therapy | |
dc.subject | multiple myeloma | |
dc.subject | severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) | |
dc.subject | Humans | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.subject | Multiple Myeloma | |
dc.subject | Vaccination | |
dc.subject | Immunity | |
dc.subject | United Kingdom | |
dc.subject | Antibodies, Viral | |
dc.title | Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-02-14 | |
dc.date.updated | 2023-06-02T10:27:32Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1111/bjh.18714 | |
rioxxterms.licenseref.startdate | 2023-06-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36895158 | |
pubs.issue | 5 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Myeloma Molecular Therapy | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1111/bjh.18714 | |
pubs.volume | 201 | |
icr.researchteam | Myeloma Molecular Therapy | |
dc.contributor.icrauthor | Kaiser, Martin | |
icr.provenance | Deposited by Mr Arek Surman on 2023-06-02. Deposit type is initial. No. of files: 1. Files: Br J Haematol - 2023 - Faustini - Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody.pdf | |